Journal of Clinical Oncology · 2021 · 255 citations · 25 references
MedicineHematologyPharmacotherapyHematologic OncologyImmunotherapyMolecular OncologyBone Marrow EvaluationCancer ImmunotherapyCombination ImmunotherapyHematologic Malignancy TherapyMinimal Residual DiseaseMultiple MyelomaClinical Next-generation SequencingCytogenetic AbnormalitiesLenalidomide TherapyMinimal Residual Disease - Directed TherapyMinimal Residual Disease-guided TherapyMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma Treatment
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use and duration of Dara-KRd post-autologous hematopoietic cell transplantation (AHCT) and treatment cessation in patients with two consecutive MRD-negative assessments. METHODS This multicenter, single-arm, phase II trial enrolled patients with NDMM with planed enrichment for high-risk cytogenetic abnormalities (HRCAs). Patients received Dara-KRd induction, AHCT, and Dara-KRd consolidation, according to MRD status. MRD was evaluated by NGS at the end of induction, post-AHCT, and every four cycles (maximum of eight cycles) of consolidation. Primary end point was achievement of MRD negativity (< 10 –5 ). Patients with two consecutive MRD-negative assessments entered treatment-free MRD surveillance. RESULTS Among 123 participants, 43% had none, 37% had 1, and 20% had 2+ HRCA. Median age was 60 years (range, 36-79 years), and 96% had MRD trackable by NGS. Median follow-up was 25.1 months. Overall, 80% of patients reached MRD negativity (78%, 82%, and 79% for patients with 0, 1, and 2+ HRCA, respectively), 66% reached MRD < 10 –6 , and 71% reached two consecutive MRD-negative assessments during therapy, entering treatment-free surveillance. Two-year progression-free survival was 87% (91%, 97%, and 58% for patients with 0, 1, and 2+ HRCA, respectively). Cumulative incidence of MRD resurgence or progression 12 months after cessation of therapy was 4%, 0%, and 27% for patients with 0, 1, or 2+ HRCA, respectively. Most common serious adverse events were pneumonia (6%) and venous thromboembolism (3%). CONCLUSION Dara-KRd, AHCT, and MRD response-adapted consolidation leads to high rate of MRD negativity in NDMM. For patients with 0 or 1 HRCA, this strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance.
25
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal, Valérie Lauwers‐Cancès, Gérald Marit et al. · New England Journal of Medicine · 2012 · 1.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +13
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister et al. · New England Journal of Medicine · 2012 · 1.1K citations · Full text
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text
Medicine, Oncology, Pharmacotherapy +13